Evidence map›Paper›PMID 33668746›Full record

ReviewMolecules (Basel, Switzerland)2021

Polymeric Micelles in Cancer Immunotherapy.

Zhuoya Wan, Ruohui Zheng, Pearl Moharil, Yuzhe Liu, Jing Chen, Runzi Sun, Xu Song, Qiang Ao

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Zhuoya WanInstitute of Regulatory Science for Medical Device, National Engineering Research Center for Biomaterials, Sichuan University, Chengdu 610064, China.
Ruohui ZhengDepartment of Pharmaceutical Science, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA.
Pearl MoharilDepartment of Cell Biology, Harvard Medical School, Harvard University, Boston, MA 02115, USA.
Yuzhe LiuDepartment of Materials Engineering, Purdue University, West Lafayette, IN 47906, USA.
Jing ChenInstitute of Regulatory Science for Medical Device, National Engineering Research Center for Biomaterials, Sichuan University, Chengdu 610064, China.
Runzi SunDepartment of Immunology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15261, USA.
Xu SongInstitute of Regulatory Science for Medical Device, National Engineering Research Center for Biomaterials, Sichuan University, Chengdu 610064, China.ORCID 0000-0001-8537-6434
Qiang AoInstitute of Regulatory Science for Medical Device, National Engineering Research Center for Biomaterials, Sichuan University, Chengdu 610064, China.ORCID 0000-0002-1309-1971
Sichuan University · CNUniversity of Pittsburgh · USHarvard University · USPurdue University West Lafayette · US

Funding

National Key R&D Program of China 2017YFA0105802, 2020YFF0426289National Natural Science Foundation of China 32001002Sichuan Science and Technology Program 2020YFH0008
6 · The paper itself

Abstract

Cancer immunotherapies have generated some miracles in the clinic by orchestrating our immune system to combat cancer cells. However, the safety and efficacy concerns of the systemic delivery of these immunostimulatory agents has limited their application. Nanomedicine-based delivery strategies (e.g., liposomes, polymeric nanoparticles, silico, etc.) play an essential role in improving cancer immunotherapies, either by enhancing the anti-tumor immune response, or reducing their systemic adverse effects. The versatility of working with biocompatible polymers helps these polymeric nanoparticles stand out as a key carrier to improve bioavailability and achieve specific delivery at the site of action. This review provides a summary of the latest advancements in the use of polymeric micelles for cancer immunotherapy, including their application in delivering immunological checkpoint inhibitors, immunostimulatory molecules, engineered T cells, and cancer vaccines.

Indexed as

ImmunotherapyAnimalsDrug Delivery SystemsHumansMicellesNanomedicineNanoparticlesNeoplasmsPolymersMicellesPolymerscancer immunotherapymicellespolymeric nanoparticles

Identifiers

PMID33668746
PMCPMC7956602
OpenAlexW3131208335

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.